Developing a UK Wide Health Data Research Platform
We are planning a Technology Sector Symposium to start a conversation with potential partners to help us develop the new platform for the Digital Innovation Hub. Details of our event are below and you can register your interest in attending the event by emailing firstname.lastname@example.org.
Note that registrations for this event will close at 12 noon on 26 September 2018.
This symposium is mainly aimed at those in the technology sector and organisations who can help us build the platform.
Date: Tuesday 2 October 2018
Location: Wellcome Trust, Gibbs Building, 215 Euston Road, London, NW1 2BE
Chair: Gerry Reilly; Chief Technology Officer, Health Data Research UK
Purpose of symposium
The primary aim of the symposium is to brief potential platform partners on the DIH programme and interest them in the opportunity to work with us to develop it. This will be achieved by:
- Informing the technology sector of the aims of the Digital Innovation Hub programme as part of the Industrial Strategy Challenge Fund
- Establishing the mutual benefits to patients, the NHS, researchers and innovators
- Welcoming industry participation in co-development of the research platform
- Defining key requirements for successful delivery of the Digital Innovation Hub platform
- Facilitating collaboration across industry/academia/NHS to support this delivery
- Decision makers in the health technology sector
The format of the symposium will be a combination of networking, talks, panel discussion and group discussion.
£650m for UK’s life sciences sector may contribute to improved clinical trials
26 May 2023
HDR UK welcomes the Chancellor of the Exchequer’s pledge of £650 million for the UK’s life sciences including £121 million to improve clinical trials to bring new medicines to patients faster.
EMPA-KIDNEY trial: Effect of empagliflozin on chronic kidney disease progression
7 December 2022
EMPA-KIDNEY is an international clinical trial by Oxford Population Health scientists in collaboration with academics spanning eight countries. The study recruited over 6000 participants to...
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
21 June 2022
A large-scale clinical trial of a monoclonal antibody treatment for COVID-19 showed that it could reduce deaths by 21 per cent in people who had not mounted a natural antibody response of their own.